Solvency ratios also known as long-term debt ratios measure a company ability to meet long-term obligations.
Paying user area
Try for free
AbbVie Inc. pages available for free this week:
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to AbbVie Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Solvency Ratios (Summary)
Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
The analysis of the financial leverage and debt-related ratios over the observed periods reveals several key trends and shifts in the company's capital structure.
- Debt to Equity Ratio
- This ratio shows marked volatility throughout the timeline. Initially, it ranged moderately around values between approximately 5.7 and 6.6 during 2020 and 2021, indicating a consistent reliance on debt relative to shareholders' equity. Beginning in 2022, the ratio generally trended downward, hitting a low near 3.67 by December 2022, suggesting a temporary reduction in debt relative to equity. However, from 2023 onward, the ratio surged sharply, culminating in a peak of 49.22 by June 2025, which reflects a considerable increase in leverage and potentially higher financial risk.
- Debt to Capital Ratio
- The debt to capital ratio remained relatively stable early on, fluctuating slightly around the 0.85 to 0.87 range during 2020 and 2021. In 2022 and 2023, the ratio saw a slight decrease towards 0.79, implying a modest reduction in the proportion of debt in the overall capital base. From 2024 onwards, the ratio increased steadily, reaching nearly 1.0 by June 2025, reflecting a capital structure almost entirely composed of debt.
- Debt to Assets Ratio
- This ratio exhibited a declining trend from 0.74 in March 2020 down to about 0.45 in late 2023, indicating a gradual decline in debt relative to total assets during this period. Nonetheless, starting in 2024, the ratio stabilized around 0.50 to 0.51, suggesting that about half of the company’s assets are financed with debt going into 2025.
- Financial Leverage Ratio
- Financial leverage mirrored the fluctuations seen in the debt to equity ratio. It ranged from about 9.8 to 11.5 in the early period (2020-2021), dipped to a low near 8.0 by late 2022, then escalated sharply from 10.14 in early 2023 to an extreme level of 95.89 by mid-2025. This spike indicates a substantial increase in the use of debt financing relative to equity, pointing to magnified financial risk and potentially increased burden on earnings through interest costs.
Overall, the data suggest that the company experienced a period of moderately high leverage with some reduction between 2021 and 2023, followed by an aggressive increase in debt levels relative to equity, capital, and assets, particularly in recent quarters through mid-2025. The dramatic rise in leverage ratios highlights a shift towards a more debt-intensive capital structure, which could have significant implications for financial risk and future funding flexibility.
Debt Ratios
Debt to Equity
Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||||||
Short-term borrowings | |||||||||||||||||||||||||||||
Current portion of long-term debt and finance lease obligations | |||||||||||||||||||||||||||||
Long-term debt and finance lease obligations, excluding current portion | |||||||||||||||||||||||||||||
Total debt | |||||||||||||||||||||||||||||
Stockholders’ equity (deficit) | |||||||||||||||||||||||||||||
Solvency Ratio | |||||||||||||||||||||||||||||
Debt to equity1 | |||||||||||||||||||||||||||||
Benchmarks | |||||||||||||||||||||||||||||
Debt to Equity, Competitors2 | |||||||||||||||||||||||||||||
Amgen Inc. | |||||||||||||||||||||||||||||
Bristol-Myers Squibb Co. | |||||||||||||||||||||||||||||
Danaher Corp. | |||||||||||||||||||||||||||||
Eli Lilly & Co. | |||||||||||||||||||||||||||||
Gilead Sciences Inc. | |||||||||||||||||||||||||||||
Johnson & Johnson | |||||||||||||||||||||||||||||
Merck & Co. Inc. | |||||||||||||||||||||||||||||
Pfizer Inc. | |||||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. | |||||||||||||||||||||||||||||
Vertex Pharmaceuticals Inc. |
Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q2 2025 Calculation
Debt to equity = Total debt ÷ Stockholders’ equity (deficit)
= ÷ =
2 Click competitor name to see calculations.
The analysis of the quarterly financial data reveals several key trends in the company's leverage and equity position over the observed period.
- Total Debt
- The total debt exhibits a fluctuating but generally declining trend from the first quarter of 2020 through the end of 2023, decreasing from approximately $67 billion to about $59 billion. However, starting in early 2024, there is a notable increase in total debt, reaching nearly $70 billion by mid-2025. This resurgence suggests renewed borrowing or financing activities in the most recent quarters.
- Stockholders’ Equity (Deficit)
- Stockholders’ equity shows a significant recovery starting with a negative balance in the first quarter of 2020, quickly turning positive by the second quarter of 2020 and remaining positive through the end of 2023. The equity peaked around the fourth quarter of 2022 at approximately $17 billion before displaying a persistent decline starting in 2023. By mid-2025, equity has declined substantially, even becoming slightly negative again, indicating deteriorating net asset value or increasing liabilities surpassing assets.
- Debt to Equity Ratio
- The debt to equity ratio follows the inverse pattern of equity, with extremely high ratios at the start of the period (above 5x), then improving (falling to around 3.67 in late 2022), reflecting a stronger equity base relative to debt. However, from 2023 onwards, the ratio climbs sharply, reaching an extremely high level above 49x by mid-2025, primarily driven by the decline in equity and increase in debt levels. Such a high leverage ratio suggests elevated financial risk and possible solvency concerns.
In summary, the company experienced a phase of improvement in financial stability and equity strength from mid-2020 through late 2022. However, starting in 2023, the trends reversed with shrinking equity and rising debt, pushing leverage ratios to very high levels by mid-2025. This pattern signals increased financial risk and potential challenges in capital structure management moving forward.
Debt to Capital
Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||||||
Short-term borrowings | |||||||||||||||||||||||||||||
Current portion of long-term debt and finance lease obligations | |||||||||||||||||||||||||||||
Long-term debt and finance lease obligations, excluding current portion | |||||||||||||||||||||||||||||
Total debt | |||||||||||||||||||||||||||||
Stockholders’ equity (deficit) | |||||||||||||||||||||||||||||
Total capital | |||||||||||||||||||||||||||||
Solvency Ratio | |||||||||||||||||||||||||||||
Debt to capital1 | |||||||||||||||||||||||||||||
Benchmarks | |||||||||||||||||||||||||||||
Debt to Capital, Competitors2 | |||||||||||||||||||||||||||||
Amgen Inc. | |||||||||||||||||||||||||||||
Bristol-Myers Squibb Co. | |||||||||||||||||||||||||||||
Danaher Corp. | |||||||||||||||||||||||||||||
Eli Lilly & Co. | |||||||||||||||||||||||||||||
Gilead Sciences Inc. | |||||||||||||||||||||||||||||
Johnson & Johnson | |||||||||||||||||||||||||||||
Merck & Co. Inc. | |||||||||||||||||||||||||||||
Pfizer Inc. | |||||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. | |||||||||||||||||||||||||||||
Vertex Pharmaceuticals Inc. |
Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q2 2025 Calculation
Debt to capital = Total debt ÷ Total capital
= ÷ =
2 Click competitor name to see calculations.
- Total Debt
- The total debt exhibited a fluctuating trend over the observed periods. Beginning at approximately 67,046 million US dollars in March 2020, it increased significantly by mid-2020, reaching a peak near 87,432 million US dollars in June 2020. Subsequently, total debt generally decreased through 2022 and 2023, declining to around 59,385 million US dollars by the end of 2023. However, from March 2024 onwards, debt levels rose once more, reaching about 70,481 million US dollars by June 2025.
- Total Capital
- Total capital followed a somewhat similar pattern but with less volatility. It started at approximately 59,631 million US dollars in March 2020 and rose sharply to around 102,140 million US dollars by June 2020. After this peak, total capital gradually declined across the subsequent years, falling to roughly 69,745 million US dollars by December 2023. In 2024 and early 2025, total capital showed a mild recovery, increasing to approximately 70,298 million US dollars by June 2025.
- Debt to Capital Ratio
- The debt to capital ratio revealed notable variability correlating with the movements in debt and total capital. Initially, in March 2020, the ratio was elevated at 1.12, indicative of debt exceeding capital at that time. It then sharply decreased to approximately 0.85 by mid-2020 and remained relatively stable between 0.79 and 0.87 through 2021 to 2023, suggesting a more balanced capital structure during this period. From 2024 onwards, the ratio increased steadily, moving from 0.90 in early 2024 to a level of 1.00 by mid-2025, indicating a shift towards higher leverage, with debt equaling total capital.
- Summary Insights
- Overall, the financial data reveals an initial surge and subsequent decline in both total debt and total capital from 2020 through 2023, followed by a period of increased leverage starting in 2024. The debt to capital ratio's rise to 1.00 by mid-2025 suggests the company assumed a more leveraged position relative to its capital base during the later periods. The interplay of these metrics indicates dynamic capital management, with periods of deleveraging and increasing leverage reflecting responses to evolving financial conditions or strategic decisions.
Debt to Assets
Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||||||
Short-term borrowings | |||||||||||||||||||||||||||||
Current portion of long-term debt and finance lease obligations | |||||||||||||||||||||||||||||
Long-term debt and finance lease obligations, excluding current portion | |||||||||||||||||||||||||||||
Total debt | |||||||||||||||||||||||||||||
Total assets | |||||||||||||||||||||||||||||
Solvency Ratio | |||||||||||||||||||||||||||||
Debt to assets1 | |||||||||||||||||||||||||||||
Benchmarks | |||||||||||||||||||||||||||||
Debt to Assets, Competitors2 | |||||||||||||||||||||||||||||
Amgen Inc. | |||||||||||||||||||||||||||||
Bristol-Myers Squibb Co. | |||||||||||||||||||||||||||||
Danaher Corp. | |||||||||||||||||||||||||||||
Eli Lilly & Co. | |||||||||||||||||||||||||||||
Gilead Sciences Inc. | |||||||||||||||||||||||||||||
Johnson & Johnson | |||||||||||||||||||||||||||||
Merck & Co. Inc. | |||||||||||||||||||||||||||||
Pfizer Inc. | |||||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. | |||||||||||||||||||||||||||||
Vertex Pharmaceuticals Inc. |
Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q2 2025 Calculation
Debt to assets = Total debt ÷ Total assets
= ÷ =
2 Click competitor name to see calculations.
The financial data reveals several notable trends regarding debt levels, assets, and the debt-to-assets ratio over the examined quarterly periods.
- Total Debt
- Total debt started at a level of approximately 67 billion US dollars in the first quarter of 2020 and experienced a significant increase reaching a peak near 87 billion in mid-2020. Subsequently, there was a gradual reduction in debt levels throughout 2021 and into 2022, with total debt decreasing steadily from around 85 billion to approximately 63 billion by the end of 2022. In 2023, the debt level stabilized near 61 billion and remained relatively flat until the end of the year. However, starting in early 2024, total debt reversed this downward trend, increasing again to around 70 billion by mid-2025. The recent rise in debt suggests a shift in the company's financing or investment strategy during this period.
- Total Assets
- Total assets showed notable fluctuations over the period. Initially, assets increased sharply from about 91 billion in early 2020 to near 150 billion by the middle of 2020. Subsequently, there was a mild decline in total assets, fluctuating around the 140-150 billion range until the end of 2021. From 2022 onward, total assets experienced a gradual decrease reaching a low near 134 billion in early 2023. However, asset levels stabilized and showed some moderate growth in late 2023 and early 2024, peaking again around 148 billion mid-2024, before experiencing a mild decline towards mid-2025 to roughly 137 billion. This pattern reflects some volatility but overall indicates the company's asset base remained broadly stable after peaking in 2020.
- Debt to Assets Ratio
- The debt to assets ratio declined consistently from 0.74 in early 2020 to around 0.44 by late 2023, indicating an improvement in the capital structure with lower leverage over time. The reduction is primarily driven by declining debt levels alongside relatively stable asset values. Nonetheless, starting in 2024, the ratio reversed its downward trend, gradually rising back toward 0.51 by mid-2025. This increase correlates with the uptick in debt levels while assets experienced only a modest change, reflecting a renewed increase in leverage.
In summary, the company reduced its leverage substantially between 2020 and 2023 through a combination of decreasing debt and maintaining asset levels. However, beginning in 2024, the financial structure shifted as debt increased, leading to higher leverage ratios. The asset base experienced growth and decline cycles but remained within a relatively narrow band after the 2020 peak. These trends suggest carefully managed deleveraging in the first phase, followed by a strategic rebound in debt exposure in the most recent periods.
Financial Leverage
Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||||||
Total assets | |||||||||||||||||||||||||||||
Stockholders’ equity (deficit) | |||||||||||||||||||||||||||||
Solvency Ratio | |||||||||||||||||||||||||||||
Financial leverage1 | |||||||||||||||||||||||||||||
Benchmarks | |||||||||||||||||||||||||||||
Financial Leverage, Competitors2 | |||||||||||||||||||||||||||||
Amgen Inc. | |||||||||||||||||||||||||||||
Bristol-Myers Squibb Co. | |||||||||||||||||||||||||||||
Danaher Corp. | |||||||||||||||||||||||||||||
Eli Lilly & Co. | |||||||||||||||||||||||||||||
Gilead Sciences Inc. | |||||||||||||||||||||||||||||
Johnson & Johnson | |||||||||||||||||||||||||||||
Merck & Co. Inc. | |||||||||||||||||||||||||||||
Pfizer Inc. | |||||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. | |||||||||||||||||||||||||||||
Vertex Pharmaceuticals Inc. |
Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q2 2025 Calculation
Financial leverage = Total assets ÷ Stockholders’ equity (deficit)
= ÷ =
2 Click competitor name to see calculations.
The analysis of the quarterly financial data reveals several key trends over the observed periods. The total assets demonstrate a fluctuating but generally declining pattern from the high point recorded around mid-2020 through to the later dates in 2025. After reaching approximately US$150.5 billion in early 2020, the total assets decreased steadily to around US$134.5 billion at the end of 2023. Subsequently, some recovery is noted, with values rising again to approximately US$148.9 billion in early 2024 before declining once more toward US$137.2 billion by mid-2025.
Stockholders’ equity shows notable volatility throughout the periods. Initially negative in early 2020, stockholders’ equity sharply improves by mid-2020, becoming positive and increasing to a level of around US$15 billion before displaying a fluctuating yet generally downward trend post-2021. From a peak near US$17.2 billion at the end of 2022, equity diminishes noticeably to negative territory by mid-2025, indicating potential financial stress or increased liability levels relative to assets.
The financial leverage ratio, which reflects the proportion of total assets to equity, undergoes significant changes that align with the equity movement. It begins at a relatively high level around 10, increases steadily through 2021 and 2022, fluctuating between 8 and 13, before surging sharply from early 2024 onward. The ratio escalates dramatically to levels above 40 by the end of 2024 and an extreme 95.89 in mid-2025. This sharp increase in leverage suggests a substantial rise in debt or liabilities, possibly linked with the decreasing equity base, which could imply elevated financial risk in the most recent periods.
- Total Assets
- Show a declining trend from mid-2020 high to late 2023, with intermittent recovery in 2024 before further decline into 2025.
- Stockholders’ Equity
- Shifted from negative to positive early on, peaked around end of 2022, followed by a consistent decrease leading to negative territory in mid-2025.
- Financial Leverage
- Remains stable initially, then rises modestly through 2021 and 2022, before sharply increasing after 2023, indicating increased financial risk due to higher debt levels against a shrinking equity base.